Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juni 28, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juni 23, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juni 22, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juni 16, 20230OpmerkingenEN NL Read More
Oxurion Issues EUR 1.0 million in Bonds for Tranche 3 of the Funding Program with Atlas Special Opportunities LLC juni 15, 20230OpmerkingenEN Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas juni 15, 20230OpmerkingenEN NL Read More
Oxurion Finalizes Enrollment in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema juni 12, 20230OpmerkingenEN Read More
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC juni 12, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS juni 9, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS juni 6, 20230OpmerkingenEN NL Read More
Oxurion Announces Results of the Extraordinary Shareholders’ Meeting of 22 May 2023 juni 5, 20230OpmerkingenEN NL Read More
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC juni 1, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS mei 31, 20230OpmerkingenEN NL Read More
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from ATLAS mei 26, 20230OpmerkingenEN NL Read More
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema mei 25, 20230OpmerkingenEN Read More
